started · updated
Novo Nordisk launches 2 mg Ozempic dose in Spain
Novo Nordisk has announced the availability of a new 2 mg weekly dose of Ozempic (semaglutide) in Spain. The medication is available via medical prescription and is funded by the Spanish National Health System for the treatment of adults with type 2 diabetes.
Compared to the previous 1 mg dose, the 2 mg presentation offers increased efficacy in glycemic control and weight management. Clinical data indicates a reduction of up to 2.2% in glycated hemoglobin (HbA1c) and a weight reduction of up to 8 kg, while maintaining a similar safety profile.
Medical specialists, including endocrinologist Santiago Tofé from Son Espases University Hospital, note that this higher dosage addresses a specific clinical need. It provides an additional step for patients who do not reach their metabolic targets on the 1 mg dose, allowing for intensified treatment within the same pharmacological class without changing the mechanism of action.
Entities
Novo Nordisk · Ozempic · Santiago Tofé · Son Espases University Hospital · Spain